wherein said tumor cells further comprise a second set of peptides which [act as ligands for] bind the peptide binding fork of said MHC-I haplotype and wherein said second set of peptides are selected from the group consisting of:

(a) peptides which are different from peptides which are derived from proteins expressed by the cells of said patient; and

(b) peptides which are derived from tumor antigens which are expressed by said patient's cells and are present at a higher concentration on said tumor cells of said vaccine than on said patient's cells;

and wherein said tumor cells have been [charged] incubated in the presence of an organic polycation with one or more said peptides (a) or (b) or both (a) and (b) in such a way that said tumor cells are recognized as foreign by the immune system of said patient and trigger a cellular immune response in said patient;

and wherein said tumor cells have not been transfected with DNA coding for said second set of peptides.

48. (Once amended) The tumor vaccine of claim 36, wherein said tumor cells have been [charged] incubated with a number of different peptides.

Remarks

Reconsideration of this Application is respectfully requested.

Claims 36 and 48 are amended herein. Support for the amendments to the claims can be found, *inter alia*, at page 13, line 15 and at page 21, lines 3-9. These changes are believed to introduce no new matter, and their entry is respectfully requested.